|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2003-3-11
|
|
pubmed:abstractText |
Previous trials in the prevention of heart failure have been restricted to patients with low ejection fraction or hypertension. We assessed an angiotensin-converting enzyme (ACE) inhibitor, ramipril, to prevent the development of heart failure in high-risk patients without known low ejection fraction or heart failure.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
11
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1284-90
|
|
pubmed:dateRevised |
2010-4-12
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
|
|
pubmed:affiliation |
London Health Sciences Centre, London, Canada. malcolm.arnold@lhsc.on.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
